Atara Biotherapeutics, Inc.
ATRA
$15.63
$1.6511.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 103.20% | 93.29% | 69.07% | 54.12% | 40.55% |
| Total Depreciation and Amortization | -15.07% | 8.97% | 4.60% | 5.68% | 1.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.53% | -26.05% | -32.37% | -19.59% | -13.57% |
| Change in Net Operating Assets | -442.22% | -535.59% | -301.81% | -163.96% | -186.94% |
| Cash from Operations | 54.99% | 63.49% | 64.39% | 52.54% | 33.38% |
| Capital Expenditure | 81.29% | 87.49% | 79.89% | 83.55% | 54.92% |
| Sale of Property, Plant, and Equipment | 1,296.00% | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.38% | -92.29% | -92.91% | -90.75% | -33.90% |
| Cash from Investing | -101.13% | -92.32% | -93.04% | -90.80% | -33.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 22.76% | -6.15% | 5.81% | -2.11% | -3.64% |
| Issuance of Common Stock | 353.94% | 331.48% | 1,867.36% | 1,849.29% | 246.78% |
| Repurchase of Common Stock | -1,450.00% | -1,228.57% | -5.32% | 93.62% | 93.88% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -96.76% | -200.13% | 46.15% | 86.00% | 14,769.31% |
| Cash from Financing | 101.10% | 34.63% | 2,849.35% | 86.42% | -23.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.19% | -55.60% | 98.79% | -1,104.07% | 43.89% |